Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Rabies Vaccine (Human Diploid Cell) in People Aged 10-60 Years
NCT06132789Phase 1Completed
- Sponsor
- Ab&B Bio-tech Co., Ltd.
- Start
- Nov 2023
- Primary completion
- Aug 2024
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of rabies virus inactivated antigen, B in rabies (4 arms), sponsored by Ab&B Bio-tech Co., Ltd. Primary endpoints: Adverse Events/Reactions at 1 month, Serious Adverse Events/Reactions at 6 months and 1 more. Started Nov 2023; status: completed.
02
Drugs
rabies virus inactivated antigen, B
03
Conditions
rabies
Beyond the preview
Go deeper on NCT06132789.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06132789.